Literature DB >> 27169689

Seasonal influenza vaccination of high-risk adults.

Paul Loubet1,2, Pierre Loulergue1,2,3, Florence Galtier3,4, Odile Launay1,2,3,5.   

Abstract

INTRODUCTION: Adults at a high risk of severe influenza, because of their age and/or underlying health disorders, should receive seasonal influenza vaccination in order to reduce the incidence of severe illness and premature death. However, because current influenza vaccines are perceived to have suboptimal efficacy, vaccine coverage is below the recommended level in this population. Areas covered: This review examines, for each high-risk group, available data on influenza infection, vaccine efficacy and safety, and vaccine coverage. We conducted a literature search in the PubMed database to identify randomized controlled trials, observational studies and reviews published from 2000 through 2015 on both seasonal and pandemic influenza. Only studies published in English were considered. While the topic of this review is seasonal influenza, data on pandemics are included when relevant. Expert Commentary: Current seasonal influenza vaccines are only moderately protective, and vaccines eliciting broader and more durable immunity are therefore needed. Research on the use of higher doses, adjuvants, and a universal influenza vaccine is ongoing. Influenza vaccine coverage needs to be increased. Vaccination of contacts of high-risk individuals, including healthcare workers, should be encouraged.

Entities:  

Keywords:  Influenza; high-risk adults; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27169689     DOI: 10.1080/14760584.2016.1188696

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  5 in total

1.  Influenza Vaccine Uptake and Missed Opportunities Among the Medicare-Covered Population With High-Risk Conditions During the 2018 to 2019 Influenza Season : A Retrospective Cohort Study.

Authors:  Bo-Hyun Cho; Cindy Weinbaum; Yuping Tsai; Ram Koppaka
Journal:  Ann Intern Med       Date:  2021-11-16       Impact factor: 51.598

Review 2.  Factors influencing the immunogenicity of influenza vaccines.

Authors:  Simin Wen; Zhengyu Wu; Shuyi Zhong; Mao Li; Yuelong Shu
Journal:  Hum Vaccin Immunother       Date:  2021-03-11       Impact factor: 3.452

3.  The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.

Authors:  Ailian Zhang; Danyang Wang; Jinyao Li; Feng Gao; Xucheng Fan
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

4.  High Level Antibody Response to Pandemic Influenza H1N1/09 Virus Is Associated With Interferon-Induced Transmembrane Protein-3 rs12252-CC in Young Adults.

Authors:  Ling Qin; Dayan Wang; Dongfu Li; Yan Zhao; Yanchun Peng; Dannielle Wellington; Yanchao Dai; Huanqin Sun; Jinping Sun; Guihai Liu; Andrew McMichael; Tao Dong; Yonghong Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-05-15       Impact factor: 5.293

5.  Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years.

Authors:  Byung Wook Yoo; Chang Oh Kim; Allen Izu; Ashwani Kumar Arora; Esther Heijnen
Journal:  Infect Chemother       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.